

James Bogenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/764893/publications.pdf>

Version: 2024-02-01

10
papers

447
citations

1307594

7
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

728
citing authors

#	ARTICLE	IF	CITATIONS
1	BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. <i>Leukemia</i> , 2014, 28, 1657-1665.	7.2	171
2	Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 226-229.	1.3	122
3	Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt440.	6.3	75
4	Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. <i>Investigational New Drugs</i> , 2015, 33, 389-396.	2.6	35
5	JAK2 inhibitors in the treatment of myeloproliferative neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1755-1774.	4.1	16
6	Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 269-283.	3.8	14
7	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	3.0	11
8	Recent developments in myelofibrosis. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 125.	2.7	2
9	Abstract A202: RNAi as a tool to identify novel molecular vulnerabilities in myeloid leukemias. , 2009, , .		1
10	JAK inhibition: the key to treating myeloproliferative neoplasm?. <i>Expert Review of Hematology</i> , 2012, 5, 583-585.	2.2	0